Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors

T-cell Engaging bispecific antibodies (TcEs) that can re-direct cytotoxic T-cells to kill cancer cells have been validated in clinical studies. To date, the clinical success with these agents has mainly been seen in hematologic tumor indications. However, an increasing number of TcEs are currently b...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Vladimir Voynov, Paul J. Adam, Andrew E. Nixon, Justin M. Scheer
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2020-11-01
Serija:	Antibodies
Teme:	T-cell engagers bispecific antibodies immunotherapy oncology antibody engineering immunological synapse
Online dostop:	https://www.mdpi.com/2073-4468/9/4/65
Oznake:	Označite Brez oznak, prvi označite!